Day One Biopharmaceuticals/DAWN

$15.40

2.94%
-
1D1W1MYTD1YMAX

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its product candidates include tovorafenib, pimasertib and the VRK1 program. The Company’s lead product candidate, tovorafenib, is an investigational, oral, brain-penetrant, highly selective type II RAF kinase inhibitor. The Company’s pipeline also includes pimasertib, an investigational, oral, highly selective small molecule inhibitor of mitogen-activated protein kinases 1 and 2 (MEK-1/-2). It has initiated an open-label, multicenter, phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib as a monotherapy or in combination, which consists of two substudies. Substudy 1 is a phase IIa trial of tovorafenib as a monotherapy in patients 12 years and older.

Ticker

DAWN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jeremy Bender

Employees

155

Headquarters

Brisbane, United States

DAWN Metrics

BasicAdvanced
$1.31B
Market cap
-
P/E ratio
-$2.37
EPS
-
Beta
-
Dividend rate
$1.31B
$17.85
$9.67
687.13K
12.718
-52.11%
-55.68%
-55.65%
3.766
3.772
-9.21%

What the Analysts think about DAWN

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 8 analysts.
128.9% upside
High $50.00
Low $10.00
$15.40
Current price
$35.25
Average price target

DAWN Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-54.5M
18.22%
Profit margin
0%
-

DAWN Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 9.71%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.59
-$0.61
-$0.54
-$0.64
-
Expected
-$0.59
-$0.61
-$0.60
-$0.58
-$0.66
Surprise
-0.38%
-0.02%
-10.35%
9.71%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Day One Biopharmaceuticals stock?

Day One Biopharmaceuticals (DAWN) has a market cap of $1.31B as of April 23, 2024.

What is the P/E ratio for Day One Biopharmaceuticals stock?

The price to earnings (P/E) ratio for Day One Biopharmaceuticals (DAWN) stock is 0 as of April 23, 2024.

Does Day One Biopharmaceuticals stock pay dividends?

No, Day One Biopharmaceuticals (DAWN) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next Day One Biopharmaceuticals dividend payment date?

Day One Biopharmaceuticals (DAWN) stock does not pay dividends to its shareholders.

What is the beta indicator for Day One Biopharmaceuticals?

Day One Biopharmaceuticals (DAWN) does not currently have a Beta indicator.

What is the Day One Biopharmaceuticals stock price target?

The target price for Day One Biopharmaceuticals (DAWN) stock is $35.25, which is 129.19% above the current price of $15.38. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Day One Biopharmaceuticals stock

Buy or sell Day One Biopharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing